Direxion Daily S&P Biotech Bull 3X Shares (LABU)
| Assets | $973.33M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Shares Out | 7.52M |
| Dividend (ttm) | $0.56 |
| Dividend Yield | 0.45% |
| Ex-Dividend Date | Jun 25, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | +120.09% |
| Volume | 1,045,451 |
| Open | 129.14 |
| Previous Close | 131.10 |
| Day's Range | 122.54 - 130.59 |
| 52-Week Low | 48.40 |
| 52-Week High | 176.99 |
| Beta | 2.94 |
| Holdings | 154 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.
Top 10 Holdings
267.33% of assets| Name | Symbol | Weight |
|---|---|---|
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 48.23% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 37.96% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 31.68% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 31.56% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 30.24% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 29.58% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 24.94% |
| DREYFUS GOVT CASH MAN INS | n/a | 22.36% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 7.83% |
| DREYFUS TRSRY SECURITIES CASH MGMT | n/a | 2.96% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 25, 2024 | $0.15021 | Jul 2, 2024 |
| Mar 19, 2024 | $0.16064 | Mar 26, 2024 |
| Dec 21, 2023 | $0.20968 | Dec 29, 2023 |
| Sep 19, 2023 | $0.0404 | Sep 26, 2023 |
| Jun 21, 2023 | $0.1736 | Jun 28, 2023 |
| Dec 23, 2019 | $0.1062 | Dec 31, 2019 |
News
Buy LABU: Biotech Sector Benefits From Lower Interest Rates And AI
Seeking Alpha Quant rates LABU as a “HOLD”, but I rate it as a “BUY”. Markets expect the first interest rate cut at the September Fed meeting. LABU has strong momentum and benefits from lower interest...
LABU: A Really Bad Drift
Leveraged ETFs have a non-linear, unpredictable behavior. Here is a drift dashboard with 22 leveraged ETFs. Direxion Daily S&P Biotech Bull 3X Shares ETF is the worst. LABU is an instrument for season...
LABU: Buy As The Biotech Sector Starts A New Bull Market (Technical Analysis)
Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P Biotechnology...
LABU: Tool For Swing Traders
The Direxion Daily S&P Biotech Bull and Bear 3X Shares (LABU) provides 3x daily exposure to a biotechnology index. Levered ETFs like LABU are designed for short-term trading and may suffer tracking er...
Breakouts Everywhere As Buffett Moves To Record High $157 Billion Cash
Warren Buffett's Berkshire Hathaway has reached record-high levels of cash, with $157 billion on hand, exceeding Disney's market capitalization. The last time Buffett held record cash levels was in la...
LABU And LABD: Another Attractive Double-Short Pairs Trade
Pairing Direxion Daily's S&P Biotech Bull 3X Shares ETF with their S&P Biotech Bear 3X Shares ETF produces a low volatility couple. Shorting both assets is attractive because leveraged assets erode ov...
Biopharma Bounce-Back: From Policy Pains To Profitable Plains
The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail ...
LABU: A Levered ETF Doomed From The Start
The Direxion Daily S&P Biotech Bull 3x Shares ETF (LABU) is a high-risk, leveraged ETF that aims to yield three times the performance of the S&P Biotechnology Select Industry Index. The biotech sector...
LABU: 2 Requirements For Making Money In This Leveraged Biotech Fund
LABU is a 3X leveraged fund that has disappointed the biotech bulls. The sector looks beaten and perhaps cheap relative to long-term prospects. LABU can work for medium term returns if two requirement...
Leveraged Biotech ETFs: Hold LABU, Sell LABD
SPDR® S&P Biotech ETF, the Biotechnology Select Industry Index ETF, has an extreme short interest of 51.16%. XBI is in an uptrend since May-June 2022. Direxion Daily S&P Biotech Bull 3X Shares ETF, th...
LABU: Leveraged Biotech ETF Review
Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap a...
LABU: Opportunities For Gains Exist If Bought And Sold At Correct Price
LABU is more volatile than unleveraged funds, due to its 3-times investments in the derivatives of stocks listed in its benchmark index. During the past 4 months, biotechnology stocks performed quite ...
LABU Continues In Uptrend (Technical Analysis)
During July, LABU traded in a narrow range. In August, its uptrend has resumed. We expect that LABU's uptrend has a long way to go.
LABU And The Biotechs Look Ready To Outperform (Technical Analysis)
I believe small- and mid-cap biotech bottomed in May through June and has outperformed the broader market since then. Biotech continues to show strong relative outperformance versus the market and mos...
Leveraged Biotech ETFs: Buy LABU, Sell LABD
Starting with September 2021, LABU had a record sequence of nine consecutive months with negative returns. During the biotech downtrend from September 2021 to April 2022, LABD has returned 207%.
LABU: This 3X Leveraged Bull ETF Fails To Raise Any Optimism
Since my last coverage in the previous quarter, LABU has been on a free fall for the past 12 weeks and also recorded a huge loss over the past 6. 3X funds like LABU have the highest expense ratio and ...
LABU: A 3X Leveraged ETF Best Avoided
Extremely poor, mostly high negative return since LABU's inception.
Taking On Volatility With Geared ETFs
Direxion's Dave Mazza is seeing many traders using inverse and leveraged ETFs in the recent market movement.
LABU - A Compelling Biotech Trade
LABU, a triple ETF (3x) from Direxion Funds, tracks the S&P Biotechnology Select Industry Index.
LABU: Now Best Near-Term Cap Gain Among Leveraged-Long ETFs Say Market-Maker Hedging Deals
MMs “fill” Institutional huge Block-Trades by borrowing otherwise unavailable shares, sell short, hedge the short risk, ultimately cover shorts in accommodative market periods. Short-risk hedge-seller...
LABU Provides Leveraged Access For Risk-Taking Investors
Direxion Daily S&P Biotech Bull 3X Shares ETF is a biotechnology focused passive fund. The fund is aimed at providing three times the daily performance of its benchmark index.
ETF/ETN Breakouts Week 39 - September 2021: Short-Term Funds To Give You An Edge
This is the first public release of the weekly ETF/ETN forecast article, highlighting some strong sectors, index funds and commodities for your consideration. This report goes out weekly with live dai...
ARK: Cathie Wood And The Exquisite Art Of Tail Gunning
ARK Active ETFs are worth the management fee. Structured Lookback is introduced.
A Biotech ETF For Aggressive, Risk-Tolerant Investors
The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer's Disease.